Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Major Depression With Comorbid Anxiety S...
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether EEG-based neurofeedback targeting the emotion regulation network through swLORETA can improve emotional regulation and reduce symptoms in adults with Major Depressive Disorder (MDD) who have not responded sufficiently to first-line treatments. The main questions it aims to answer are: * Does EEG-neurofeedback improve emotional self-regulation and reduce clinical symptoms in patients with MDD with or without anxiety symptoms? * Are changes in EEG resting-state activity and stress biomarkers (e.g., cortisol) associated with clinical improvement? Researchers will compare an active neurofeedback group, a sham (placebo) neurofeedback group, and a treatment-as-usual control group to see if real-time EEG-neurofeedback leads to greater improvement in mood, emotional regulation, and neurophysiological indicators than placebo or no additional intervention. Participants will: * Receive 10 sessions of either real or sham EEG-neurofeedback (or no sessions in the control group) over 5 weeks. * Complete clinical, psychological, and neurophysiological assessments before (week 0) and after the intervention (week 6). * Provide repeated saliva samples to assess stress-related biomarkers at week 0 and week 6. * Continue their standard pharmacological treatment throughout the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Active swLORETA Z-score Neurofeedback — Participants receive 10 sessions (25 minutes each, twice per week for 5 weeks) of EEG-based neurofeedback using the NeuroGuide® software and a 24-channel EEG recording system (eego™, ANT Neuro). The neurofeedback protocol is based on real-time swLORETA Z-score training targeting brain regions involved in emotion regulation. Feedback is provided via gamified visual displays when EEG activity moves toward normative patterns. This is an operant conditioning-based protocol designed to enhance emotional self-regulation.
  • Device: Yoked-sham swLORETA Z-score Neurofeedback — Participants receive 10 sessions identical in appearance and duration to the active neurofeedback condition. However, the feedback provided is not based on their own EEG activity. Instead, it is pre-recorded data from a matched participant in the active group ("yoked" design), ensuring no real-time neurophysiological modulation occurs. The same EEG equipment and visual feedback interface are used to maintain blinding.

Primary Outcomes

  • Change in depressive symptom severity, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), from baseline to post-intervention. (From enrollment (week 0) to the end of treatment (week 6))
  • Change in depressive symptoms measured by the Hamilton Depression Rating Scale (HAM-D), from baseline to post-treatment (From enrollment (week 0) to the end of treatment (week 6))
  • Change in self-reported anxiety symptoms measured by the Beck Anxiety Inventory (BAI), from baseline to post-intervention (From enrollment (week 0) to the end of treatment (week 6))
  • Change in self-reported depressive symptoms measured by the Beck Depression Inventory-II (BDI-II), from baseline to post-intervention (From enrollment (week 0) to the end of treatment (week 6))
  • Change in salivary cortisol levels (Cortisol Awakening Response and Diurnal Slope) (From enrollment (week 0) to the end of treatment (week 6))
  • Change in cognitive emotion regulation strategies measured by the Cognitive Emotion Regulation Questionnaire (CERQ) (From enrollment (week 0) to the end of treatment (week 6))
  • Change in transient mood states measured by the Profile of Mood States (POMS) (Before and after each neurofeedback session (Sessions 1-10; Weeks 1-5))
  • Change in resting-state EEG activity (From baseline (week 0) to Post-treatment (Week 6); Before and after each neurofeedback session (Sessions 1-10; Weeks 1-5))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-19
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Corporacion Parc Tauli
Collaborators: Horizon 2020 - European Commission
Contact Information
Study Contact:
Virginia Soria, MD,PhD
+34 937231010
vsoria@gmail.com
Diego Palao, MD, PhD
+34 937231010
dpalao@tauli.cat
Virginia Soria, MD, PhD
+34 937231010
vsoria@gmail.com
Corporació Sanitària Parc Taulí de Sabadell
Interventions
  • Device: Active swLORETA Z-score Neurofeedback — Participants receive 10 sessions (25 minutes each, twice per week for 5 weeks) of EEG-based neurofeedback using the NeuroGuide® software and a 24-channel EEG recording system (eego™, ANT Neuro). The neurofeedback protocol is based on real-time swLORETA Z-score training targeting brain regions involved in emotion regulation. Feedback is provided via gamified visual displays when EEG activity moves toward normative patterns. This is an operant conditioning-based protocol designed to enhance emotional self-regulation.
  • Device: Yoked-sham swLORETA Z-score Neurofeedback — Participants receive 10 sessions identical in appearance and duration to the active neurofeedback condition. However, the feedback provided is not based on their own EEG activity. Instead, it is pre-recorded data from a matched participant in the active group ("yoked" design), ensuring no real-time neurophysiological modulation occurs. The same EEG equipment and visual feedback interface are used to maintain blinding.
Study Locations (1 sites)
Corporació Sanitària Parc Taulí de Sabadell, Sabadell, Barcelona, Cataluña 08208 Spain
Eligibility Criteria
Inclusion Criteria: * A primary diagnosis of Major Depressive Disorder (MDD), established by qualified psychiatrists according to DSM-5 criteria. * Patients with comorbid anxiety or anxiety symptoms will be included, provided that MDD is the primary diagnosis. * Participants must score at least 20 on the Montgomery-Åsberg Depression Rating Scale (MADRS), indicating a moderate level of depression. * All participants must be on a stable psychopharmacological treatment for at least 6 weeks before beginning of the study. Exclusion Criteria: * Patients with a concurrent diagnosis of MDD and other severe psychiatric disorders. * Patients with serious physical illnesses that could interfere with study participation or the interpretation of results. * Participants currently undergoing structured psychotherapy or other interventions unrelated to standard psychopharmacological treatment. * Patients presenting with active suicidal ideation, as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS), at the time of screening will not be eligible due to associated risks. * Active substance abuse or dependence (except nicotine). * Intellectual disability or conditions that interfere with the ability to provide informed consent and complete the intervention (e.g., severe visual or hearing impairments). * Pregnancy.
Conditions Breast Cancer
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the second most common cancer world-wide following lung cancer. It afflicts about 1.7 million patients annually, of which 60% mandate surgery of the breast and/or the axilla, and nearly 20-50% of them may develop post mastectomy pain syndrome . After breast cancer surgery, between 6% and 86% of people may develop tight bands of fibrous tissue under their skin, known as axillary web syndrome. These bands can cause pain in the shoulder area by trying to raise or extend the arm. Shoulder pain is a common side effect of breast cancer surgery and treatment. Various medical and interventional procedures have been tried for treating postmastectomy shoulder pain, with varying efficacy . Among the interventional procedures that may have a role for treatment. Innervation of the glenohumeral joint (GHJ) can be divided into anterior and posterior innervation from articular branches of the suprascapular nerve (SN):C5 \&6 (posterior-lateral), axillary nerve (AN):C5 \&6 (anterior-lateral, inferior, and posteriorlateral), and lateral pectoral nerve (LPN): C5 \&6 (anterior superior)

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: (Shoulder individual nerves TRF (thermal radio frequency): Patients will receive shoulder individual nerves Thermal RF. — Shoulder individual nerves thermal RF technique: The patient will be put in the sitting position, monitored with electrocardiography, pulse oximetry, and non-invasive blood pressure. after disinfection A high-frequency linear transducer (10-15 Hz) will be placed parallel and cephalad to the spine of the scapula. The probe will be moved from cephalad to caudad until the trapezius and supraspinatus muscles were identified. The suprascapular nerve will be identified as a hyperechogenic structure in the suprascapular fossa deep to the superior transverse scapular ligament. A 10 cm radiofrequency needle, with a 10 mm active tip, will be inserted in plane with the ultrasound beam and advanced to reach the proximity to the nerve. A nerve stimulator was used as an additional nerve-finding modality.
  • Drug: conservative treatment — Patients will receive conservative treatment Acetaminophen (paracetamol 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.

Primary Outcomes

  • Assess the changes in NPRS (numerical pain rating scale) for assessment of pain relief which will be recorded before treatment and at 1 month, 2 months and 3-month intervals following treatment. (1 month, 2 months and 3-month intervals following treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-01
Completion: 2026-08-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute, Egypt
Contact Information
Study Contact:
suzan Adlan
+201111068300
dr_s.adlan@hotmail.com
suzan Adlan Khedr, MD
01111068300
dr_s.adlan@hotmail.com
National Cancer institute
Interventions
  • Device: (Shoulder individual nerves TRF (thermal radio frequency): Patients will receive shoulder individual nerves Thermal RF. — Shoulder individual nerves thermal RF technique: The patient will be put in the sitting position, monitored with electrocardiography, pulse oximetry, and non-invasive blood pressure. after disinfection A high-frequency linear transducer (10-15 Hz) will be placed parallel and cephalad to the spine of the scapula. The probe will be moved from cephalad to caudad until the trapezius and supraspinatus muscles were identified. The suprascapular nerve will be identified as a hyperechogenic structure in the suprascapular fossa deep to the superior transverse scapular ligament. A 10 cm radiofrequency needle, with a 10 mm active tip, will be inserted in plane with the ultrasound beam and advanced to reach the proximity to the nerve. A nerve stimulator was used as an additional nerve-finding modality.
  • Drug: conservative treatment — Patients will receive conservative treatment Acetaminophen (paracetamol 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.
Study Locations (1 sites)
National Cancer institute, Cairo, Cairo Governorate 002 Egypt
Eligibility Criteria
Inclusion Criteria: 1. Age (18-65) Years. 2. ASA physical status (II- III). 3. Patients with post mastectomy irradiation shoulder pain. 4. Body mass index (BMI): (20-40) kg/m2. Exclusion Criteria: 1. Patient refusal. 2. Known sensitivity or contraindication to drugs used in the study. 3. Pregnancy. 4. Recent myocardial infarction. 5. Hemodynamically unstable. 6. Local and systemic sepsis. 7. Psychiatric illness.
Conditions Breast Cancer
Phase PHASE3
Enrollment 642
Locations 25 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: TQB2102 for Injection — TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer.
  • Drug: Docetaxel combined + Trastuzumab +Pertuzumab — Positive control.

Primary Outcomes

  • Objective Response Rate (Up to approximately 30 months)
  • Progression-Free Survival (Up to approximately 30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-06-23
Completion: 2030-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 642 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Zhimin Shao, Doctor
18017312288
szm@163.com
Yongmei Yin, Doctor
13951842727
ym.yin@hotmail.com
Shikai Hong, Doctor
18963789035
shikhong@163.com
Anhui Provincial Cancer Hospital
Interventions
  • Drug: TQB2102 for Injection — TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer.
  • Drug: Docetaxel combined + Trastuzumab +Pertuzumab — Positive control.
Study Locations (25 sites)
Anhui Provincial Cancer Hospital, Hefei, Anhui 230000 China
Anhui Provincial Hospital, Hefei, Anhui 230001 China
Beijing Tiantan Hospital,Capital Medical University, Beijing, Beijing Municipality 100050 China
Gansu Provincial Cancer Hospital, Lanzhou, Gansu 730050 China
Gansu Provincial Cancer Hospital, Lanzhou, Gansu 730050 China
Shantou Central Hospital, Shantou, Guangdong 515031 China
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081 China
Huaihe Hospital of Henan University, Kaifeng, Henan 475099 China
Puyang Oilfield General Hospital, Puyang, Henan 457001 China
The Third People's Hospital of Zhengzhou, Zhengzhou, Henan 450000 China
Eligibility Criteria
Inclusion Criteria: * Subjects voluntarily enrolled in this study with good compliance * Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1 * HER2 positive, recurrent or metastatic invasive breast cancer confirmed by histopathology or cell pathology * Defined hormone receptor (HR) status * Has not received systemic anti-tumor therapy during the recurrence/metastasis stage (acceptable ≤ first-line endocrine therapy) * If receiving (new) adjuvant therapy, it is required that the time interval between the end of systemic therapy (excluding endocrine therapy) and the discovery of recurrence/metastasis be greater than 12 months * Have at least one measurable lesion according to RECIST 1.1 criteria; * Good major organ function Exclusion Criteria: * It is known that there is spinal cord compression or active central nervous system metastasis; * Subjects with only skin and/or brain lesions as target lesions * Combined diseases and medical history 1. Have had or currently have other malignant tumors within the past 5 years of randomization 2. Unrelieved toxic reactions above Common Terminology Criteria (CTC) AE grade 1 caused by any previous treatment 3. Received major surgical treatment, open biopsy, or significant traumatic injury within 4 weeks prior to randomization 4. There are diseases that affect intravenous injection and venous blood collection 5. There are congenital bleeding and coagulation disorders present 6. An arterial/deep vein thrombosis event occurred within 6 months prior to the first administration 7. Poor blood pressure control 8. Suffering from significant cardiovascular disease 9. There is an uncontrolled infection of ≥ CTC AE grade 2 within 14 days before the start of treatment 10. History of interstitial lung disease/pneumonia (non infectious) requiring steroid medication intervention in the past 11. Individuals with moderate to severe pulmonary dysfunction/disease within 3 months prior to the first administration 12. Active viral hepatitis with poor control 13. Active syphilis infected individuals in need of treatment 14. Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation 15. Immunosuppressants or systemic or absorbable local hormone therapy are required to achieve immunosuppression 16. History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases 17. Urine routine shows urinary protein ≥++and confirms 24-hour urinary protein quantification\>1.0 g 18. Patients with renal failure requiring hemodialysis or peritoneal dialysis 19. Poor control of diabetes 20. Individuals with epilepsy who require treatment 21. Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders * Tumor related symptoms and treatment 1. There is a third interstitial fluid accumulation or cancerous lymphangitis that cannot be controlled by drainage or other methods 2. History of cumulative dose exposure to anthracyclines in the past 3. Received radiation therapy within 3 weeks prior to the start of study treatment and endocrine therapy within 2 weeks prior to the start of study treatment 4. Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks before the start of the study treatment * Research treatment related 1. Previously received antibody conjugate therapy consisting of topoisomerase I inhibitors,; 2. Allergic to any research drug or any ingredient or excipient in the drug; 3. Individuals who experience severe hypersensitivity reactions after using monoclonal antibodies; 4. Participated in other clinical trials of anti-tumor therapy within 4 weeks before the start of the research treatment. * According to the researcher's judgment, there are situations that seriously endanger the safety of the subjects or affect their ability to complete the study.
Conditions Bronchial Asthma, Bronchiectasis, ILD, C...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Research is being conducted into chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, and bronchiectasis. The investigation specifically focuses on sleep-disordered breathing (SDB) in individuals with chronic respiratory disease. SDB encompasses a range of conditions, the most common of which is obstructive sleep apnoea. In obstructive sleep apnoea, periodic pauses in breathing (apnoea) lead to reduced blood oxygen levels. To detect these events, patients typically undergo sleep studies that involve monitoring oxygen saturation, heart rate, and respiratory patterns during sleep. When chronic respiratory disease and SDB coexist, breathing disturbances during sleep may be exacerbated. To identify SDB, sleep studies are commonly used to assess oxygen levels, heart rate, and breathing patterns. The objective of this research is to identify differences between patients with chronic respiratory diseases who have SDB and those who do not. This will be achieved by analysing sleep study data using a novel analytical approach. The aim is to determine whether this method can yield more detailed insights into the underlying pathophysiology of these conditions.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Changes in respiratory signals entropy, oxygen saturation , and heart rate recorded using cardiorespiratory polygraphy during a 1-hour daytime and overnight sleep in healthy subjects and patients with chronic respiratory diseases with /without SDB. (2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-30
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University College, London
Collaborators: Royal Free Hospital NHS Foundation Trust
Contact Information
Study Contact:
Nawal Alotaibi
02080168375
n.alotaibi@ucl.ac.uk
Nawal Alotaibi, Phd student
02080168375
n.alotaibi@ucl.ac.uk
Royal Free hospital
Interventions
N/A
Study Locations (1 sites)
Royal Free hospital, London, NW3 2QG United Kingdom
Eligibility Criteria
Inclusion Criteria: * All adult patients (≥ 18years) with chronic respiratory disease with/without SDB. * patients who have had previously negative studies as a control group. * Subject is able to read, understand, and sign the informed consent form. * Willing to sleep with portable monitoring devices. Exclusion Criteria: * Patients who are under 18 years of age at the time of the index study. * Contraindications to the use of portable monitoring. * Inability to give informed consent to take part in the study.
Conditions Advanced Breast Cancer
Phase PHASE2
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This multicenter, prospective phase II clinical trial evaluates the efficacy and safety of sequential Trastuzumab rezetecan followed by dalpiciclib plus endocrine therapy (fulvestrant or aromatase inhibitors) in 45 patients with HR+/HER2-low/ultra-low advanced breast cancer. Enrolled patients will receive Trastuzumab rezetecan monotherapy for 6-8 cycles until clinical benefit, then transition to CDK4/6 inhibitors with endocrine therapy until disease progression or unacceptable toxicity. The primary endpoint is progression-free survival (PFS), with secondary endpoints including objective response rate (ORR), overall survival (OS), and treatment-related adverse events (TRAEs). The study will be conducted at Sun Yat-sen Memorial Hospital and collaborating centers.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy — sequential Trastuzumab rezetecan followed by CDK4/6 inhibitors (Dalpiciclib, Abemaciclib, Ribociclib, Palbociclib) plus endocrine therapy (fulvestrant or aromatase inhibitors)

Primary Outcomes

  • Progression-free survival (PFS) (2-year PFS)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-18
Completion: 2030-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigators:
  • JianLi Zhao, PhD (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
JianLi Zhao, PhD
008615920589334
zhaojianli1988@126.com
Jianli Zhao
+8615920589334
zhaojianli1988@126.com
Sun Yat-sen Memorial Hospital
Interventions
  • Drug: Trastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy — sequential Trastuzumab rezetecan followed by CDK4/6 inhibitors (Dalpiciclib, Abemaciclib, Ribociclib, Palbociclib) plus endocrine therapy (fulvestrant or aromatase inhibitors)
Study Locations (1 sites)
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong 510120 China
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria: 1\. Female patients aged ≥18 years. 2. Pathologically confirmed HER2-low/ultra-low, HR-positive unresectable or metastatic breast cancer: 1. HER2-low: IHC 1+ or IHC 2+/ISH-negative;HER2-ultra-low: IHC 0 with membranous staining (\>0 but \<1+). HR+: ≥10% tumor cells with ER/PR nuclear staining (verified by central pathology review). 2. Disease stage: Recurrent/metastatic disease; locally recurrent cases must be deemed unresectable by investigators. 3\. Prior therapy: 1. Disease progression after endocrine therapy (ET) + CDK4/6 inhibitor in the advanced/metastatic setting. 2. Progression within 12 months of adjuvant ET + CDK4/6 inhibitor allowed. 3. ≤1 line of prior ET and ≤1 line of chemotherapy for advanced disease. 4. Measurable disease per RECIST 1.1 (including lytic/mixed bone-only metastases). 5\. ECOG PS 0-1. 6. Adequate organ function (no transfusions/G-CSF within 2 weeks prior): 1. Hematologic: ANC \>1.5×10⁹/L; platelets \>90×10⁹/L; Hb \>90 g/L. 2. Hepatic: Total bilirubin ≤ULN (≤2×ULN if Gilbert's syndrome). ALT/AST ≤1.5×ULN (≤5×ULN with liver metastases). Alkaline phosphatase ≤2.5×ULN. 3. Renal: BUN/Cr ≤1.5×ULN. 4. Cardiac: LVEF ≥50%; 5. QTcF \<470 ms. 7. Voluntary participation with signed informed consent. Exclusion Criteria: Participants will be excluded if they meet any of the following conditions: 1. Prior anti-HER2 therapy at any stage (including HER2-ADCs such as T-DM1 or T-DXd). 2. Significant cardiac disease, including: 1\) Heart failure or systolic dysfunction (LVEF \<50%). 2) High-risk/treated angina or arrhythmias (e.g., Type II Mobitz II/third-degree AV block, ventricular tachycardia). 3\) Clinically significant valvular disease. 4) ECG-confirmed transmural myocardial infarction. 5) Uncontrolled hypertension (systolic \>150 mmHg and/or diastolic \>100 mmHg). 3. Interstitial lung disease (ILD)/pneumonitis: 1. History of non-infectious ILD requiring steroids. 2. Current ILD or suspected ILD that cannot be ruled out by imaging at screening. 4. Impaired drug absorption due to: 1\) Dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting oral medication intake. 5\. Uncontrolled third-space effusions (e.g., pleural/peritoneal effusions) not manageable by drainage. 6\. Pregnancy, lactation, or unwillingness to use effective contraception during and for 7 months post-treatment. 7\. Other exclusions: 1. Severe comorbidities interfering with treatment (e.g., active HBV, pulmonary infections requiring therapy). 2. Any condition deemed unsuitable by investigators.
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to explore the experience of the chronic disease, with a particular focus on self-care, in adults with type 2 diabetes mellitus. The main questions it aims to answer are: * what is the association between self-care and glycated hemoglobin over time? * what are participants' clinical and sociodemographic characteristics influencing self-care behaviors? Participants' socio-demographic and clinical data will be collected by medical records and, at the beginning or at the end of the clinical standard outpatient visit, they will be asked to complete study questionnaires. The results of this study could be helpful in providing quality assistance, improving resource consumption, and reducing the onset of complications.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Self-care in diabetes [1] (The SCODI will be administered at the following time point: T0 - Baseline.)
  • Self-care in diabetes [2] (The SCODI will be administered by telephone at the following time point: T0.5 - Month 6 ± 28 days)
  • Self-care in diabetes [3] (The SCODI will be administered by telephone at the following time point: T1 - Month 12 ± 28 days.)
  • Self-care in diabetes [4] (The SCODI will be administered by telephone at the following time point: T1.5 - Month 18 ± 28 days.)
  • Self-care in diabetes [5] (The SCODI will be administered by telephone at the following time point: T2 - Month 24 ± 28 days.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-01
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Milano Bicocca
Collaborators: IRCCS Policlinico S. Donato
Principal Investigators:
  • Davide LL Ausili (STUDY_DIRECTOR) - Università degli Studi di Milano - Bicocca
Contact Information
Study Contact:
Davide LL Ausili
+39 0264488032
davide.ausili@unimib.it
Michela Luciani
+39 0264488168
michela.luciani@unimib.it
Rosario Caruso, RN, PhD
rosario.caruso@grupposandonato.it
IRCCS Policlinico San Donato
Interventions
N/A
Study Locations (2 sites)
IRCCS Policlinico San Donato, San Donato Milanese, Milan 20097 Italy
Fondazione IRCCS San Gerardo dei Tintori, Monza, Monza Brianza 20900 Italy
Eligibility Criteria
Inclusion Criteria: * Diagnosis of type 2 diabetes; * Age over 18 years old; * Adequate comprehension of the Italian language; * Signed and dated informed consent. Exclusion Criteria: * Presence of documented psychiatric or neurodegenerative disease; * Pregnancy; * Any condition that, by the investigators' judgment, may limit adherence to study procedures
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most commonly diagnosed cancer worldwide and is the leading cause of cancer-related deaths in women. Mammography, breast ultrasonography (US), and breast magnetic resonance imaging (MRI) are essential for the diagnosis and follow-up of breast cancer. The American College of Radiology Breast Imaging- Reporting and Data System (ACR BI-RADS), which is used worldwide, provides the standard terminology for breast imaging (Jajodia et al., 2021). The ACR BI- RADS lexicon categorizes breast imaging findings into seven BIRADS categories of 0, 1, 2, 3, 4(4a, 4b, 4c), 5, and 6 according to the probability of malignancy. Breast imaging findings assigned as BI-RADS 4 require tissue sampling and histopathological examination. However, the likelihood of malignancy of lesions classified as BI-RADS 4 ranges widely, from 3% to 94%. Categorization of lesions according to BI-RADS is related to the experience of the radiologist, with experienced radiologists performing better than inexperienced radiologists

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions — Compare MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions

Primary Outcomes

  • Diagnostic performance of combining apparent diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-01
Completion: 2026-01-01
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: Not specified
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mansoura University Hospital
Principal Investigators:
  • Mohamed AbdElmoniem (PRINCIPAL_INVESTIGATOR) - Lecturer of faculty of medicine Mansoura university
Contact Information
Study Contact:
Mohamed AbdElmoniem
01014008473
dr.m1993@mans.edu.eg
Maryam Hamdy foaud
01016881450
Maryamhamdy@mans.edu.eg
Mohamed AbdElmoniem
01014008473
dr.m1993@mans.edu.eg
Mohamed AbdElmoniem
Interventions
  • Diagnostic Test: MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions — Compare MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions
Study Locations (1 sites)
Mohamed AbdElmoniem, Al Mansurah, 35516 Egypt
Eligibility Criteria
Inclusion Criteria: * Patients with BI-RADS 4 lesion. Exclusion Criteria: * Patients on chemotherapy or related treatment. * Patients who have contraindications to do MRI as patients with cardiac pace maker, patients with cochlear implant and ocular foreign body, claustrophobia.
Conditions Diabetes, Diabetes Mellitus, Diabetes Ty...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators aim is to conduct a randomized clinical trial in an underserved population who are either uninsured or on Medicaid and taking at least one injection of insulin daily. The investigators believe that this study will lead to considerable alleviation of health disparities and provide better care for an underserved population. This will be a pilot study to evaluate the feasibility of such a trial in this population before doing a larger multicenter trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: Continuous Glucose Monitoring (CGM) — Continuous glucose monitors will be placed subcutaneously every 14 days.

Primary Outcomes

  • Change in Glycated hemoglobin (HbA1c) between baseline and 6-month visits for both groups (Baseline, 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-19
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tulane University
Collaborators: Abbott
Principal Investigators:
  • Shaveta Gupta, MD (PRINCIPAL_INVESTIGATOR) - Tulane University
Contact Information
Study Contact:
Neha Upadhyay, BDS,MPH
5049889803
nupadhyay@tulane.edu
Ayitevi Agbodji, MD,MPH&TM
504-988-9839
aagbodji@tulane.edu
Neha Upadhyay, BDS,MPH
504-988-9803
nupadhyay@tulane.edu
University Medical Center
Interventions
  • Device: Continuous Glucose Monitoring (CGM) — Continuous glucose monitors will be placed subcutaneously every 14 days.
Study Locations (1 sites)
University Medical Center, New Orleans, Louisiana 70112 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years * Type 2 diabetes mellitus * HbA1C ≥ 7.5% * At least on 1 insulin injection therapy daily * Patients established with primary care clinic or endocrinology clinic or diabetes clinics in the New Orleans and surrounding areas * Patients with Medicaid or free care or uninsured * Patients must be able to speak and understand English and be capable of providing informed consent to participate in the study Exclusion Criteria: * Type 1 diabetes mellitus * Currently on CGM or using insulin pump * Advanced renal disease or Estimated Glomerular Filtration Rate (eGFR) \<40 * Serious co-morbidities which in the investigator's opinion, will make it challenging for patients to participate * The patient has been diagnosed with end-stage renal disease, is on dialysis, or has had a kidney transplant, Hemoglobinopathies, iron therapy or other condition that interferes with HbA1c measurement * Pregnant
Conditions Treatment Resistant Depression (TRD)
Phase PHASE4
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The trial utilizes a pragmatic, randomized, open label design with two parallel arms. Participants aged 18-65 with a diagnosis of unipolar depressive disorder and without stable remission in the past 12 months are randomized 1:1 to receive either algorithm guided treatment (AGT) or treatment as usual (TAU). The AGT approach incorporates pre-defined treatment steps, critical decision points, and "if-then" rules based on symptom response. It leverages prior treatment history, current symptomatology, and tolerability profiles to personalize the therapeutic sequence and reduce treatment inertia. In contrast, TAU reflects standard clinical practice, where treatment decisions are left to clinician discretion without algorithmic structure. The primary objective of the study is to determine whether AGT leads to a greater reduction in depressive symptoms over a 12-week treatment period, as measured by the 6-item Hamilton Depression Rating Scale (HAMD-6). Secondary objectives include evaluating cognitive and psychosocial functioning, suicide risk, treatment adherence, tolerability, number of medication changes, and long-term outcomes at a 24-week follow-up, providing insights into the longer-term trajectory of TRD management.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Algorithm guided treatment (AGT) — AGTs consist of strategies (which treatments to use), tactics (how to implement each treatment) and treatment steps (in what order to implement the different treatments). Furthermore, AGTs also define critical decision points during the treatment at which the effects of a certain treatment are assessed and based on this assessment recommend specific treatment revisions according to preset "if-then rules." This is most often done by implementing measurement-based care.
  • Other: Treatment as usual (TAU) — TAU includes the standard clinical care for patients with TRD as determined by a senior consultant.

Primary Outcomes

  • Hamilton Depression Scale, 6 item version (HAMD-6) (From baseline to end of study (12 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-08-13
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aalborg University Hospital
Principal Investigators:
  • René Ernst Nielsen, Prof., MD, PhD (PRINCIPAL_INVESTIGATOR) - Aalborg University Hospital, Psychiatry, Denmark
Contact Information
Study Contact:
Deni Rkman, MD
+4593856194
deni.rkman@rn.dk
Simon Johansen, MsN
+4561395631
simon.johnsen@rn.dk
Deni Rkman, MD
+4593856194
deni.rkman@rn.dk
Aalborg University Hospital
Interventions
  • Other: Algorithm guided treatment (AGT) — AGTs consist of strategies (which treatments to use), tactics (how to implement each treatment) and treatment steps (in what order to implement the different treatments). Furthermore, AGTs also define critical decision points during the treatment at which the effects of a certain treatment are assessed and based on this assessment recommend specific treatment revisions according to preset "if-then rules." This is most often done by implementing measurement-based care.
  • Other: Treatment as usual (TAU) — TAU includes the standard clinical care for patients with TRD as determined by a senior consultant.
Study Locations (1 sites)
Aalborg University Hospital, Aalborg, 9000 Denmark
Eligibility Criteria
Inclusion Criteria: 1. A diagnosis of unipolar depressive disorder according to ICD-10 based on documented completion of the Mini International Neuropsychiatric Interview, version 7.0.2 (MINI 7.0.2) at Screening and confirmed by medical records or a healthcare professional. 2. Have not achieved stable remission of depression in 12 months at investigator's clinical assessment. 3. Severity of depression: A score of at least 21 on the self-reported Major Depression Inventory (MDI). 4. Age criteria: Subjects must be at least 18 years old and below 65 at the time of randomization. 5. Signed document of informed consent. 6. The participant is an outpatient. 7. No significant change in medical treatment in the last 4 weeks before screening visit. 8. The patient is pharmacologically treated for depression. Exclusion Criteria: 1. A diagnosis of dementia. 2. Substance misuse influencing study participation as judged by the investigator. 3. High risk of non-adherence at the investigator's discretion. 4. Not understanding the Danish language as judged by the investigator. 5. Suicidality according to C-SSRS with a positive response to question 4 or 5 within the last three months or upon investigator's discretion. 6. Medical conditions such as cancer, kidney failure, epilepsy, deep brain stimulation device, or other medical conditions interfering with study the outcome and safety as judged by investigator's discretion.

Empowering Narratives

NCT07062042
Recruiting
Conditions PTSD - Post Traumatic Stress Disorder, D...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: The Russian invasion of Ukraine has resulted in forced displacement, with over 80,000 Ukrainian refugees now residing in Norway. This displacement has led to increased vulnerability to trauma and mental health challenges. Narrative Exposure Therapy (NET), a short-term trauma-focused intervention, has demonstrated efficacy in reducing PTSD symptoms among individuals exposed to organized violence and war. Aim: The protocol aims to assess the clinical effects of Narrative Exposure Therapy (NET) on PTSD and depression symptoms among Ukrainian refugees in Norway and to facilitate training and supervised practice for Ukrainian health professionals and workers in using NET. Methods: This study employs a pretest-posttest randomized controlled experimental design. Ukrainian health professionals and workers in Norway will receive standardized NET training through a digital course. Subsequently, they will treat Ukrainian refugees using NET under supervision. Participants will be screened and assessed at three time points: baseline, immediately after treatment, and at 6-month follow-up. Validated questionnaires in Ukrainian and Russian will be used: PHQ-9, ITQ, LEC-5, SHUT-D, and demographic questionnaire. Exclusion criteria include active psychotic spectrum disorders, neurodevelopmental disorders and concurrent trauma therapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Narrative Exposure Therapy — Narrative Exposure Therapy (NET) is a short-term, trauma-focused intervention developed for individuals exposed to multiple traumatic events, including refugees and survivors of war and organized violence. It is grounded in principles of cognitive-behavioral therapy and testimonial therapy. NET helps adults reconstruct a coherent narrative of their life by integrating fragmented traumatic memories through structured exposure within a chronological autobiographical framework. Core components include lifeline construction, imaginal exposure to traumatic events, and reprocessing of emotional responses. The method emphasizes stabilization through therapeutic structure and is supported by evidence from randomized controlled trials showing reductions in PTSD symptoms. The approach is protocol-driven and applicable in low-resource settings under supervision, as outlined in the practice document.

Primary Outcomes

  • PTSD Symptom Severity (ITQ) (Baseline, Post-treatment (one to seven days after the last treatment session), 6-month Follow-up (counted after the post-treatment screening))
  • Dissociation Symptoms (Shut-D) (Baseline, Post-treatment (one to seven days after the last treatment session), 6-month Follow-up (counted after the post-treatment screening))
  • Depression Symptoms (PHQ-9) (Baseline, Post-treatment (one to seven days after the last treatment session), 6-month Follow-up (counted after the post-treatment screening))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2026-04-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kristiania University College
Collaborators: University of Konstanz, Oswaldo Cruz Foundation, Mental helse, Vårsta Diakoni, Norsk-Ukrainsk hjelpeorganisasjon, The Dam Foundation
Principal Investigators:
  • Vanessa Nolasco Ferreira, Associate Professor, PhD (PRINCIPAL_INVESTIGATOR) - Kristiania University of Applied Sciences
Contact Information
Study Contact:
Vanessa Nolasco Ferreira, Associate Professor, PhD
+4741231069
vanessanolasco.ferreira@kristiania.no
Ashley Rebecca Bell-Mizori, Master in Psychology
vanessanolasco.ferreira@kristiania.no
Vanessa Nolasco Ferreira, Associate Professor, PhD
+4741231069
vanessanolasco.ferreira@kristiania.no
Kristinia University of Applied Sciences
Interventions
  • Behavioral: Narrative Exposure Therapy — Narrative Exposure Therapy (NET) is a short-term, trauma-focused intervention developed for individuals exposed to multiple traumatic events, including refugees and survivors of war and organized violence. It is grounded in principles of cognitive-behavioral therapy and testimonial therapy. NET helps adults reconstruct a coherent narrative of their life by integrating fragmented traumatic memories through structured exposure within a chronological autobiographical framework. Core components include lifeline construction, imaginal exposure to traumatic events, and reprocessing of emotional responses. The method emphasizes stabilization through therapeutic structure and is supported by evidence from randomized controlled trials showing reductions in PTSD symptoms. The approach is protocol-driven and applicable in low-resource settings under supervision, as outlined in the practice document.
Study Locations (1 sites)
Kristinia University of Applied Sciences, Oslo, 0187 Norway
Eligibility Criteria
Inclusion Criteria: * Ukrainian refugee residing in Norway. * Arrival in Norway after 24 February 2022. * Minimum 18 years old * Provided informed consent for participation. * Classified as having PTSD symptoms (ITQ) OR reported traumatic experience (LEC-5) OR present PTSD comorbidities (PHQ-9, Shut-D). Exclusion Criteria: * Diagnosis, history, or scores compatible with the psychotic spectrum * Diagnostic of neurodevelopmental disorders * Current participation in ongoing trauma-focused psychological treatment (e.g., therapy for PTSD). * Declining consent for mandatory elements of the study (e.g., participation in screening or treatment delivery).
Conditions Suicidal Ideation, Suicide Attempt, Anxi...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pilot study is to test the effectiveness of a novel intervention for young adults (ages 18-27) with mental health conditions who have been released from an acute care psychiatric facility. The intervention aims to reduce suicidality, depression, anxiety, re-hospitalization, and improve mental health recovery by using outpatient services. The current standard of care (SOC) for these patients at discharge includes a discharge plan with a list of their medications, anticipated outpatient appointments, and information on when and where to find community resources. The intervention being tested involves the implementation of a mental health recovery education and support program, involving one-on-one and small group meetings led by Peer Support Specialists (PSS) and Recovery Community Organizations (RCO). Participants will be assigned to either Cohort A or B for 8 weeks. Cohort A will be the intervention group with PSS and RCOs. * Weeks 1-4: One-on-one meetings with PSS for education and support. Assessments will be completed at weeks 2 and 4. * Weeks 5 and 7: One-on-one meetings with PSS for education and support. * Week 6 and 8: Group meetings with PSS and other participants from RCOs. Assessments will be completed during these weeks. Cohort B will be the SOC group with no PSS or RCOs. * Weeks 1-4: Weekly check in phone calls with a member of the research team. Assessments will be completed at weeks 2 and 4. * Weeks 5-8: Check in phone calls with a member of the research team every other week. Assessments will be completed at weeks 6 and 8. Data collected from participant assessments, adherence to medication, and re-admittance to a psychiatric facility will be used to compare the intervention to the SOC.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Peer Support Services Recovery — A program of mental health recovery through one-on-one and small group meetings with a PSS and RCOs for individuals recently discharged from an acute care psychiatric facility.

Primary Outcomes

  • Change in suicidal ideation (Weeks 2, 4, 6, and 8.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2027-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Principal Investigators:
  • Joseph Guillory, M.D. (PRINCIPAL_INVESTIGATOR) - University of Texas Southwestern Medical Center
Contact Information
Study Contact:
Noureen Hoq
214-648-0311
noureen.hoq@utsouthwestern.edu
Interventions
  • Behavioral: Peer Support Services Recovery — A program of mental health recovery through one-on-one and small group meetings with a PSS and RCOs for individuals recently discharged from an acute care psychiatric facility.
Study Locations (1 sites)
The University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria: * Chief complaint of suicidal ideation, suicide attempt, depression, and/or anxiety * discharged from inpatient care or from emergency department * men and women ages 18-27 Exclusion Criteria: * primary diagnosis of: substance use disorder, schizophrenia spectrum, intellectual development disorder, autism spectrum disorder (level II or III)
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 450
Locations 50 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Azetukalner — Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
  • Drug: Placebo — Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks

Primary Outcomes

  • Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6 (Baseline to Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-07-08
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xenon Pharmaceuticals Inc.
Contact Information
Study Contact:
Xenon Medical Affairs
1-604-484-3300
XenonCares@xenon-pharma.com
Interventions
  • Drug: Azetukalner — Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
  • Drug: Placebo — Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Study Locations (50 sites)
Harmonex Neuroscience Research, Dothan, Alabama 36303 United States
University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville, Alabama 35801 United States
Pillar Clinical Research, Bentonville, Arkansas 72712 United States
SanRo Clinical Research Group, Bryant, Arkansas 72022 United States
Clinical Innovations Inc, Bellflower, California 90706 United States
Center for Neurohealth, La Jolla, California 93037 United States
Artemis Institute for Clinical Research, San Diego, California 92103 United States
California Neuroscience Research, Sherman Oaks, California 91403 United States
Pacific Clinical Research Management Group, Upland, California 91786 United States
Institute of Living, Hartford, Connecticut 06106 United States
Eligibility Criteria
Key Inclusion Criteria: * Adults ≥18 and ≤74 years of age and experienced their first major depressive episode (MDE) prior to 50 years of age * Body Mass Index (BMI) ≤40 kg/m2 * Meets the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revised (DSM-5-TR) criteria for current major depressive disorder and is currently in an MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI) * Participant's current MDE has a duration of ≥6 weeks and ≤24 months. Key Exclusion Criteria: * Participant has a primary diagnosis of a mood disorder other than MDD. * Participant has a history of any of the following: MDD with psychotic or catatonic features; MDD with mixed features; Bipolar I or II disorder; Obsessive-compulsive disorder; Schizophrenia, primary thought disorder, or other psychotic disorder. * Participant has a current diagnosis of any of the following: MDD with seasonal pattern; Depression with peripartum or perimenopausal onset; Post traumatic stress disorder; Antisocial or borderline personality disorder (or presence of clinically significant borderline personality traits); Panic disorder and/or agoraphobia; ADHD treated with a psychostimulant, diagnosed during the current MDE, or with unstable symptoms, as judged by the investigator. * Participant has a substance (excluding tobacco) or alcohol use disorder within the 12 months prior to screening. * Participant has had an active suicidal plan/intent within the 6 months prior to screening, presence of suicidal behavior in the last 2 years, or \>1 suicide attempt \> 24 years of age. * Participant has a history of non-suicidal self-harm behavior in the 12 months prior to screening. * Participant has used antidepressants or other prohibited medications (including benzodiazepines), within the 2 weeks (4 weeks for fluoxetine) or within a period less than 5 times the drug's half-life, whichever is longer, prior to randomization. * Participant has a history of non-response to ≥2 antidepressant drugs of adequate dose and duration in the current MDE as determined by the Antidepressant Treatment Response Questionnaire (ATRQ). * Participants with medical conditions that may interfere with the purpose or conduct of the study * Participant is pregnant, breastfeeding, or planning to become pregnant.